Grail, Inc.
A healthcare company that makes the Galleri test, a single blood draw that can screen for dozens of types of cancer at once by spotting DNA fragments shed by tumors. The company was born in 2016 when DNA-sequencing firm Illumina spun it out after researchers noticed, while testing pregnant women, that tumor DNA could be found in a routine blood sample. Its name comes from the "holy grail" of medicine—a simple, non-invasive test that catches cancer early.
Sold 1.00M
Sold 216.7K
Granted 115.6K · Sold 201.3K
Granted 60.1K · Sold 85.2K
Sold 1.5K
Granted 6.9K
Granted 6.4K
Granted 5.5K
Granted 6.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Illumina, Inc.10% owner · 1 transaction | -22.2% | 3.50M | — | — | 1.00M |
| Ragusa Robert PChief Executive Officer, Director · 11 transactions | -29.4% | 518.6K | — | — | 216.7K |
| Ofman Joshua J.Chief Executive Officer, Director · 14 transactions | -17.5% | 402.3K | 115.6K | — | 201.3K |
| Freidin AaronChief Financial Officer · 9 transactions | -8.6% | 260.7K | 60.1K | — | 85.2K |
| Partridge Andrew JohnChief Growth Officer · 1 transaction | — | 163.7K | — | — | 1.5K |
| Summe Gregory LDirector · 4 transactions | +17.9% | 45.2K | 6.9K | — | — |
| Chase William JDirector · 4 transactions | +17.6% | 42.7K | 6.4K | — | — |
| Krevans SarahDirector · 1 transaction | +14.8% | 42.6K | 5.5K | — | — |
| Mizell StevenDirector · 4 transactions | +17.6% | 42.6K | 6.4K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: -1.50M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.